Consumers Unable to Decode Genomics-Based Tests on Their Own

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- A report released by Cogent Research reveals that a majority of Americans support government involvement in the distribution of direct-to-consumer genomics-based tests. This and other findings are explored in more detail in the 5th edition of the Cogent Genomics, Attitudes & Trends study (CGAT™ 2010).

The CGAT™ study, based on a nationally representative survey of 1,000 Americans, reveals that 56% of Americans say genomics-based tests sold directly to consumers through websites, pharmacies, or other retail outlets should require FDA approval. Only 16% say the tests should be available without FDA approval, with the remaining 28% saying they are “not sure.”

“Americans themselves admit they know very little about genomics-based testing, but their interest levels are high, so they are looking for someone to put a stamp of approval on them – in this case the FDA,” said Cogent Research Principal, Christy White.

Not only are Americans looking for help from the FDA when it comes to DTC genomics-based tests, they anticipate reaching out to their primary care physicians as well. When asked to imagine that their personal genetic profile indicated they may be at risk for cancer, 84% said they would talk to their doctor as the next step in the process. Only 7% say they would not do anything with this information.

“Americans’ willingness to reach out to their physicians is most likely borne out of their confusion regarding just what the results from a genetic test can tell a person. When given a list of five ways test results can be interpreted, responses were all over the map,” added Ms. White.

About CGAT™. The fifth annual Cogent Genomics Attitudes & Trends (CGAT™) provides an updated understanding of how recent advancements in DTC access, legal protections, and increased media coverage have impacted Americans’ awareness, acceptance, and preferences for genomics-based benefits, products, and solutions. From personalized nutrition to personalized medicine, the report provides a detailed exploration of the barriers and catalysts to adoption.

About Cogent Research. Cogent Research helps clients gain clarity, obtain perspective, and formulate direction on critical business issues. Founded in 1996, Cogent provides custom research, syndicated research products, and evidence-based consulting to leading organizations in the financial services and life sciences industries. Through quality research, advanced analytics, and deep industry knowledge, Cogent Research delivers data-driven solutions and strategies that enable clients to better understand customers, define products, and shape market opportunities in order to increase revenues and grow the value of their products and brands.



CONTACT:

Cogent Research
Valerie Small, 617-715-7637
[email protected]
www.cogentresearch.com

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Women  Health  Biotechnology  Genetics  Pharmaceutical  Research  Consumer  Science  Men

MEDIA:

Logo
 Logo

Suggested Articles

Belén Garijo, currently CEO of Merck Healthcare, will succeed Stefan Oschmann as the German company's chief exec when his tenure ends in April 2021.

More than 60 researchers and bioethicists called on Pfizer to take time to collect more COVID-19 vaccine safety data, Bloomberg reports. 

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.